Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clearmind Medicine Inc. (CMND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Clearmind submits current reports on Form 6-K and annual reports on Form 20-F under the Securities Exchange Act of 1934, reflecting its status as a clinical-stage psychedelic pharmaceutical biotech company listed on Nasdaq and the Frankfurt Stock Exchange.
Through these filings, investors can review press releases that are formally incorporated by reference into Clearmind’s registration statements on Form F-3 and Form S-8. Recent Form 6-K reports have attached announcements about the FDA-approved Phase I/IIa clinical trial of CMND-100 for alcohol use disorder, including positive top-line results from the first cohort, Data and Safety Monitoring Board approval to continue the trial, and expansion of the multinational clinical-site network. Other 6-K filings describe capital-raising transactions such as registered direct offerings of common shares and pre-funded warrants, with stated uses of proceeds for operating expenses, research and development, clinical and pre-clinical testing, working capital, and general corporate purposes.
Clearmind’s filings also document corporate actions relevant to CMND stock, including a 1-for-40 reverse share split and Nasdaq notifications regarding minimum bid price and stockholders’ equity requirements. These documents outline how the company has addressed exchange listing criteria and how related matters are monitored by Nasdaq. In addition, the filings identify Clearmind’s principal executive offices in Vancouver, British Columbia, and provide details on its intellectual property-focused business model and clinical-stage status.
On Stock Titan, Clearmind’s SEC filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the context and key points of lengthy reports, making it easier to locate information on clinical trial disclosures, financing terms, and listing compliance without reading every page in detail. Users can also review historical filings to understand how Clearmind’s development programs, capital structure, and regulatory communications have evolved over time.
Clearmind Medicine Inc. is reducing the second tranche of its previously announced convertible promissory note financing from an aggregate principal amount of $1,900,000 to $600,000, with a cash purchase price equal to 90% of principal, or $540,000. The first tranche for $600,000 in principal, generating $540,000 in cash proceeds, closed on February 4, 2026. These tranches form part of a broader facility of up to $10,000,000 in convertible promissory notes with CLA Investors. The company states that the reduction reflects its current capital requirements and liquidity position, while all other terms of the second-tranche notes remain unchanged.
Clearmind Medicine Inc. received an amended Schedule 13G from Iroquois Capital Management, Richard Abbe and Kimberly Page reporting beneficial ownership through warrants. The filing states that Iroquois Capital Management and Kimberly Page each beneficially own 131,886 shares of common stock issuable upon exercise of warrants, representing 8.1% of the class. Richard Abbe is reported as beneficially owning 166,464 shares issuable upon exercise of warrants, representing 9.99% of the common stock. These amounts reflect warrant terms that block exercises above 9.99% ownership, or 4.99% for certain warrants. The percentages are based on 1,499,838 common shares outstanding as of January 19, 2026, and the filers certify the securities are not held for the purpose of changing or influencing control of Clearmind.
Clearmind Medicine Inc. reports updates to its previously announced convertible loan arrangement with institutional investors. The company has issued and sold additional convertible promissory notes with an aggregate principal amount of
On
Clearmind Medicine Inc. reports additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa trial of CMND-100, an oral, non-hallucinogenic MEAI-based drug candidate for treating alcohol use disorder. Another six patients completed treatment with no serious adverse events and overall good tolerability, reinforcing the favorable safety profile seen in the first cohort.
The multinational study evaluates safety, tolerability, pharmacokinetics and preliminary efficacy in patients with moderate to severe alcohol use disorder at sites including Johns Hopkins University and leading Israeli medical centers. Clearmind is a clinical-stage psychedelic pharmaceutical biotech with nineteen patent families and 31 granted patents focused on underserved conditions such as alcohol use disorder.
Clearmind Medicine Inc. has entered a development agreement with Polyrizon Ltd. to create an intranasal formulation of its proprietary, non-hallucinogenic neuroplastogen MEAI. The goal is to enhance drug delivery and support ongoing and future clinical programs targeting addiction-related and other central nervous system disorders.
The collaboration combines Clearmind’s neuroplastogen expertise with Polyrizon’s intranasal hydrogel technology to potentially improve bioavailability, therapeutic effect and patient experience. Polyrizon is a related party under Canadian securities rules, and Clearmind is relying on available exemptions from formal valuation and minority shareholder approval for this related party transaction.
Clearmind Medicine Inc. is drawing additional funding under previously agreed convertible note financing. The company will issue and sell convertible promissory notes with an aggregate principal amount of $2,500,000, for a cash purchase price equal to 90% of principal, or $2,250,000.
The first tranche closed on February 4, 2026 with $600,000 principal for $540,000 in cash. A second tranche of $1,900,000 principal for $1,710,000 in cash will close after Clearmind files a registration statement covering resale of the common shares issuable upon conversion of the notes.
Clearmind Medicine reports that its proprietary compound MEAI (5-MeO-AI), a next-generation, non-hallucinogenic neuroplastogen, has been specifically named in new bipartisan U.S. legislation, the Expanding Veterans’ Access to Emerging Treatments Act of 2026 (H.R. 7091).
The bill would direct the U.S. Department of Veterans Affairs to create investigational research and extended access treatment programs using emerging therapies for unmet medical needs in veterans. Covered therapies include psilocybin, MDMA, MEAI, 5-MeO-DMT, ibogaine, ketamine and others designated by the VA Secretary.
This is the first time MEAI has been referenced in U.S. federal legislation. Clearmind highlights potential applications for conditions such as Alcohol Use Disorder and post-traumatic stress disorder, emphasizing growing policy recognition of innovative, evidence-based psychedelic and neuroplastogen approaches.